Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and leading to ...

Explore innovative treatments for spinal cord injury in clinical trials, including Lineage's OPC1 and NervGen's NVG-291, ...

Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.

Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.

Find out about Resolution Therapeutics' macrophage therapy, as it just raised $85 million in a series B round.

The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.

Glucagon-like peptide-1 (GLP-1) receptor agonists, originally approved as treatment in type-2 diabetes, recently became a tremendous success in the obesity market. Currently, subcutaneous delivery – ...